Cangpo Liujun Prescription
Phase 2Small molecule
Cangpo Liujun Prescription is one of 49 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Fudr
PfizerPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Botensilimab
AAgenus Inc.
Phase 3
Zanzalintinib
Merck & Co.Phase 3
5-Fu
TToray Industries, Inc
Phase 3
Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
TQB2102
CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
Calcium Levofolinate
FFujian Cancer Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cangpo Liujun Prescription. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details